ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 474,85
0,89%
Dow Jones
42 297,12
0,86%
DAX
20 250,08
0,56%
Brent Oil
80,275
-0,01%
Bitcoin
96 789,43
2,41%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Pharvaris NV (PHVS)

  7. Pharvaris NV (PHVS) Actualités

PHVS

Pharvaris NV (PHVS)

Pharvaris NV
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:PHVS
DateHeureSourceTitreSymboleSociété
13/01/202512h50GlobeNewswire Inc.Pharvaris Outlines 2025 Strategic PrioritiesNASDAQ:PHVSPharvaris NV
02/12/202422h27Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PHVSPharvaris NV
13/11/202422h12Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:PHVSPharvaris NV
13/11/202422h10GlobeNewswire Inc.Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business UpdatesNASDAQ:PHVSPharvaris NV
12/11/202412h50GlobeNewswire Inc.Pharvaris to Participate in the Guggenheim Healthcare Innovation ConferenceNASDAQ:PHVSPharvaris NV
24/10/202414h00GlobeNewswire Inc.Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific MeetingNASDAQ:PHVSPharvaris NV
16/10/202412h50GlobeNewswire Inc.Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific MeetingsNASDAQ:PHVSPharvaris NV
15/10/202412h50GlobeNewswire Inc.Pharvaris to Host Virtual Investor Event on October 23, 2024NASDAQ:PHVSPharvaris NV
03/10/202412h50GlobeNewswire Inc.Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership WorkshopNASDAQ:PHVSPharvaris NV
05/09/202412h50GlobeNewswire Inc.Pharvaris Provides Business Update and Expands Development Program for DeucrictibantNASDAQ:PHVSPharvaris NV
05/09/202412h49GlobeNewswire Inc.Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024NASDAQ:PHVSPharvaris NV
05/09/202412h48GlobeNewswire Inc.Pharvaris Presents Data at the Bradykinin Symposium 2024NASDAQ:PHVSPharvaris NV
28/08/202412h50GlobeNewswire Inc.Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin SymposiumNASDAQ:PHVSPharvaris NV
14/08/202412h50GlobeNewswire Inc.Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PHVSPharvaris NV
11/06/202412h50GlobeNewswire Inc.Pharvaris Announces Annual Meeting of ShareholdersNASDAQ:PHVSPharvaris NV
04/06/202412h50GlobeNewswire Inc.Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent CongressesNASDAQ:PHVSPharvaris NV
13/05/202412h50GlobeNewswire Inc.Pharvaris to Present Clinical and Nonclinical Data at Upcoming CongressesNASDAQ:PHVSPharvaris NV
08/05/202422h10GlobeNewswire Inc.Pharvaris Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:PHVSPharvaris NV
10/04/202422h10GlobeNewswire Inc.Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:PHVSPharvaris NV
10/04/202422h08GlobeNewswire Inc.Pharvaris Appoints David Nassif, J.D., as Chief Financial OfficerNASDAQ:PHVSPharvaris NV
04/04/202412h50GlobeNewswire Inc.Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 ConferenceNASDAQ:PHVSPharvaris NV
18/03/202411h50GlobeNewswire Inc.Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE CongressesNASDAQ:PHVSPharvaris NV
06/03/202422h40Edgar (US Regulatory)Form F-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:PHVSPharvaris NV
06/03/202412h50GlobeNewswire Inc.Pharvaris to Present Deucrictibant Clinical Data at Upcoming CongressesNASDAQ:PHVSPharvaris NV
05/03/202412h50GlobeNewswire Inc.Pharvaris to Participate in the Leerink Global Biopharma Conference 2024NASDAQ:PHVSPharvaris NV
22/02/202412h50GlobeNewswire Inc.Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual MeetingNASDAQ:PHVSPharvaris NV
16/02/202412h50GlobeNewswire Inc.Pharvaris Announces Extraordinary Meeting of ShareholdersNASDAQ:PHVSPharvaris NV
26/01/202412h50GlobeNewswire Inc.Pharvaris to Present at the WSAAI Annual Meeting 2024NASDAQ:PHVSPharvaris NV
22/01/202413h35Dow Jones NewsPharvaris Says FDA Lifted Clinical Hold on Application for DeucrictibantNASDAQ:PHVSPharvaris NV
22/01/202412h50GlobeNewswire Inc.Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE AttacksNASDAQ:PHVSPharvaris NV
 Showing the most relevant articles for your search:NASDAQ:PHVS

Dernières Valeurs Consultées

ASX
DOU
Douugh
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés